GlassScriptPhysician profile
Liet N Le
NPI 1477726214
$90,060.68
in general payments reported to CMS, 2019-2025
39 companies · $4,277 in 2025
The $4,277 reported for 2025 was more than what 87% of Procedural Dermatology providers received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,030 · 2020: $1,701 · 2021: $2,991 · 2022: $13K · 2023: $42K · 2024: $22K · 2025: $4,277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Food and Beverage: $13K · Consulting Fee: $3,180 · Travel and Lodging: $2,122 · Education: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $49,918.75 |
| Food and Beverage | $13,160.08 |
| Consulting Fee | $3,180.00 |
| Travel and Lodging | $2,122.20 |
| Education | $249.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $33,997.35 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $29,018.18 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Galderma Laboratories, L.P. | $4,118.13 | 2019-2025 | Aklief, Oracea, Epsolay |
| Dermavant Sciences, INC. | $4,069.95 | 2022-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $2,042.57 | 2019-2024 | Jublia, Arazlo, Siliq |
| Journey Medical Corporation | $1,748.01 | 2019-2025 | |
| Abbvie INC. | $1,730.78 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,467.06 | 2019-2025 | |
| Genzyme Corporation | $1,379.67 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,073.34 | 2020-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $1,041.62 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Pfizer INC. | $988.82 | 2019-2025 | |
| Ucb, INC. | $961.74 | 2019-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $945.58 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $919.29 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $840.97 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $695.58 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $551.04 | 2019-2025 | Anzupgo, Adbry |
| Amgen INC. | $527.12 | 2020-2025 | Otezla |
| Almirall LLC | $492.31 | 2019-2025 | Klisyri, Seysara |
| Celgene Corporation | $244.04 | 2019 | |
| Encore Dermatology INC. | $206.13 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $178.45 | 2021-2022 | |
| Biofrontera INC. | $140.92 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $125.22 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.18 | 2024 | Spevigo |
| Organon LLC | $81.65 | 2025 | Vtama |
| Dermira, INC. | $51.44 | 2020-2021 | |
| Vyne Pharmaceuticals INC. | $51.11 | 2020 | |
| Carl Zeiss Meditec, INC. | $48.16 | 2019 | |
| Epi Health, LLC | $42.11 | 2021 | |
| Bausch Health US, LLC | $39.07 | 2023 | Jublia, Siliq, Targretin |
| Verrica Pharmaceuticals INC. | $28.30 | 2023 | Ycanth |
| Organogenesis INC. | $22.67 | 2022 | |
| Botanix Sb INC | $21.88 | 2025 | Sofdra |
| Kerecis Limited | $16.16 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Paratek Pharmaceuticals, INC. | $15.87 | 2025 | Nuzyra |
| Sebela Pharmaceuticals INC. | $12.81 | 2021 | |
| Medimetriks Pharmaceuticals, INC. | $12.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Liet Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.